Cytek BioSciences, Inc. (CTKB): Price and Financial Metrics
GET POWR RATINGS... FREE!
CTKB POWR Grades
- Sentiment is the dimension where CTKB ranks best; there it ranks ahead of 87.63% of US stocks.
- CTKB's strongest trending metric is Growth; it's been moving up over the last 177 days.
- CTKB's current lowest rank is in the Momentum metric (where it is better than 11.34% of US stocks).
CTKB Stock Summary
- With a one year PEG ratio of 0.49, CYTEK BIOSCIENCES INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.17% of US stocks.
- CTKB's went public 1.53 years ago, making it older than just 3.23% of listed US stocks we're tracking.
- CTKB's price/sales ratio is 11.55; that's higher than the P/S ratio of 89.63% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to CYTEK BIOSCIENCES INC are IAS, DDOG, YPF, STE, and KALU.
- To dig deeper into the stock's financial statements, go to CTKB's page on browse-edgar?action=getcompany&CIK=0001831915.
CTKB Valuation Summary
- CTKB's price/sales ratio is 10.2; this is 100% higher than that of the median Healthcare stock.
- Over the past 19 months, CTKB's EV/EBIT ratio has gone up 5459.1.
Below are key valuation metrics over time for CTKB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CTKB | 2023-01-30 | 10.2 | 3.8 | -1657.0 | 5613.9 |
| CTKB | 2023-01-27 | 10.4 | 3.9 | -1688.1 | 5747.1 |
| CTKB | 2023-01-26 | 10.2 | 3.8 | -1647.1 | 5571.7 |
| CTKB | 2023-01-25 | 10.1 | 3.7 | -1631.6 | 5505.4 |
| CTKB | 2023-01-24 | 9.8 | 3.6 | -1590.6 | 5330.0 |
| CTKB | 2023-01-23 | 9.6 | 3.5 | -1549.4 | 5154.3 |
CTKB Price Target
For more insight on analysts targets of CTKB, see our CTKB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $27.00 | Average Broker Recommendation | 1.67 (Moderate Buy) |
CTKB Stock Price Chart Interactive Chart >
CTKB Price/Volume Stats
| Current price | $13.39 | 52-week high | $16.05 |
| Prev. close | $13.24 | 52-week low | $7.38 |
| Day low | $12.77 | Volume | 1,017,400 |
| Day high | $13.51 | Avg. volume | 753,748 |
| 50-day MA | $11.50 | Dividend yield | N/A |
| 200-day MA | $12.15 | Market Cap | 1.81B |
Cytek BioSciences, Inc. (CTKB) Company Bio
Cytek Biosciences, Inc. engages in the manufacture and sale of cell analysis solutions for clinical and biomedical research in the fields of drug discovery, genomics, immuno-oncology, immuno-profiling, infectious diseases, inflammatory diseases, and multi-site standardization applications. Its instruments include the Aurora and Northern Lights systems, which are flow cytometers to deliver cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The company also offers cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. Its customers include pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. Cytek Biosciences, Inc. was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. The company was incorporated in 2014 and is headquartered in Fremont, California.
Latest CTKB News From Around the Web
Below are the latest news stories about CYTEK BIOSCIENCES INC that investors may wish to consider to help them evaluate CTKB as an investment opportunity.
Cytek Biosciences (NASDAQ:CTKB) shareholders have endured a 37% loss from investing in the stock a year agoThe simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make... |
Should You Invest in Cytek Biosciences (CTKB) for a Long-Term?Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Strategy” Q3 2022 investor letter. A copy of the same can be downloaded here. The Small Company Composite returned -3.06% in the quarter compared to 0.24% for the Russell 2000 Growth Index. The rise in interest rates and inflation concerns drove […] |
Cytek Biosciences to Participate in the Piper Sandler Healthcare ConferenceFREMONT, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY. Cytek management is scheduled to participate in a fireside chat on Thursday, December 1st at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the com |
Cytek® Biosciences Introduces Cytek CloudNew Digital Ecosystem Supports Full Spectrum Flow Cytometry Research – from Panel Design to Data Acquisition Cytek® Cloud Cytek® Cloud is the new digital ecosystem that supports full spectrum flow cytometry research from panel design to data acquisition. FREMONT, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the launch of Cytek Cloud – a cloud-based platform that features two integrated tools to streamline workflows on Cytek’s state-of-the-art c |
Cytek Biosciences Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagCytek Biosciences ( NASDAQ:CTKB ) Third Quarter 2022 Results Key Financial Results Revenue: US$40.5m (up 18% from 3Q... |
CTKB Price Returns
| 1-mo | 23.52% |
| 3-mo | -7.78% |
| 6-mo | -13.33% |
| 1-year | -5.57% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 31.15% |
| 2022 | -37.44% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...